By Jennifer Chiou
New York, Jan. 3 - Spirus Medical, Inc. announced it acquired $5.9 million in a series A round of financing.
Investors included BioVentures Investors, Point Judith Capital and Village Ventures.
The Stoughton, Mass., company also said it obtained 510(k) clearance from the FDA for its Endo-Ease Endoluminal Advancement System (EAS), which, with a conventional flexible endoscope, uses rotation for a more efficient approach to gastrointestinal endoscopy.
"This funding provides us with the resources to begin manufacturing and commercialization of the Endo-Ease product line later this year," Ross Garofalo, Spirus chief financial officer, said in a news release.
The company added that Marc Goldberg of BioVentures Investors, Gina Raimondo of Point Judith Capital and Michael Benoit, an individual investor, have joined its board.
Spirus Medical develops diagnostic and therapeutic advancement systems for gastroenterology, urology and gynecology.
| Issuer: | Spirus Medical, Inc.
|
| Issue: | Preferred stock
|
| Amount: | $5.9 million
|
| Round: | Series A
|
| Investors: | BioVentures Investors, Point Judith Capital, Village Ventures
|
| Announcement date: | Jan. 3
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
